Initiative aims to increase awareness of the
relationship between chronic heartburn and esophageal cancer, and
role of EsoGuard esophageal precancer testing
NEW
YORK, Oct. 1, 2024 /PRNewswire/ -- Lucid
Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the
"Company"), a commercial-stage, cancer prevention medical
diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM),
today announced that it held its inaugural educational session and
#CheckYourFoodTube Precancer Testing Event targeting former NFL
players in Cincinnati, Ohio.
This initiative aims to increase awareness of the relationship
between gastroesophageal reflux disease (GERD), also known as
chronic heartburn, and highly lethal esophageal cancer, as well as
the opportunity to prevent this cancer through esophageal precancer
detection using Lucid's EsoGuard® Esophageal DNA Test.
The event, hosted by Brian J. deGuzman, M.D., Lucid's Chief
Technology and Compliance Officer, featured a comprehensive
educational session followed by on-site testing of Cincinnati-based former NFL players who are at
risk of having esophageal precancer. Lucid plans to expand these
educational and testing events targeting former NFL players to
other cities across the nation.
"Collaborating with Lucid Diagnostics on this inaugural event is
just the beginning of what we hope will be a game-changing
initiative for former NFL players across the country," said
Solomon Wilcots, former NFL player
for the Cincinnati Bengals and Team Leader of Sports-Health
Alliance at Russo Partners. "As athletes who've put our bodies on
the line throughout our careers, we have a heightened awareness of
the importance of protecting our long-term health. EsoGuard offers
us a crucial opportunity for early detection of esophageal
precancer, which can truly be a lifesaver. I strongly encourage all
my peers in the sports community to take proactive steps in
safeguarding their health from this deadly, yet preventable cancer.
Remember, when it comes to esophageal cancer, early detection is
the best—it's time we all 'Check Our Food Tubes!'."
"These educational and precancer testing events targeting former
NFL players provide us with a great opportunity to increase
awareness of highly lethal but now preventable esophageal cancer,"
said Lishan Aklog, M.D., Lucid's
Chairman and Chief Executive Officer. "Individuals with heartburn
and other risk factors (age over 50, male, white race, obesity,
smoking or a family history), whether former NFL players or their
legions of fans, can now undergo a quick and simple test to
determine whether they may have precancer and take appropriate
steps to prevent this cancer. We are committed to getting the word
out and appreciate Mr. Wilcots and his compatriots using their
platform to help us do so."
About Lucid Diagnostics
Lucid Diagnostics Inc. is a
commercial-stage, cancer prevention medical diagnostics company and
subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the
millions of patients with gastroesophageal reflux disease (GERD),
also known as chronic heartburn, who are at risk of developing
esophageal precancer and cancer. Lucid's EsoGuard®
Esophageal DNA Test, performed on samples collected in a brief,
noninvasive office procedure with its EsoCheck®
Esophageal Cell Collection Device, represent the first and only
commercially available tools designed with the goal of preventing
cancer and cancer deaths through widespread, early detection of
esophageal precancer in at-risk patients.
For more information about Lucid, please visit www.luciddx.com
and for more information about its parent company PAVmed, please
visit www.pavmed.com.
Forward-Looking Statements
This press release includes
forward-looking statements that involve risk and uncertainties.
Forward-looking statements are any statements that are not
historical facts. Such forward-looking statements, which are based
upon the current beliefs and expectations of Lucid's management,
are subject to risks and uncertainties, which could cause actual
results to differ from the forward-looking statements. Risks and
uncertainties that may cause such differences include, among other
things, volatility in the price of Lucid's common stock; general
economic and market conditions; the uncertainties inherent in
research and development, including the cost and time required to
advance Lucid's products to regulatory submission; whether
regulatory authorities will be satisfied with the design of and
results from Lucid's clinical and preclinical studies; whether and
when Lucid's products are cleared by regulatory authorities; market
acceptance of Lucid's products once cleared and commercialized;
Lucid's ability to raise additional funding as needed; and other
competitive developments. In addition, Lucid continues to monitor
the COVID-19 pandemic and the pandemic's impact on Lucid's
businesses. These factors are difficult or impossible to predict
accurately and many of them are beyond Lucid's control. In
addition, new risks and uncertainties may arise from time to time
and are difficult to predict. For a further list and description of
these and other important risks and uncertainties that may affect
Lucid's future operations, see Part I, Item 1A, "Risk Factors," in
Lucid's most recent Annual Report on Form 10-K filed with the
Securities and Exchange Commission, as the same may be updated in
Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form
10-Q filed by Lucid Diagnostics after its most recent Annual
Report. Lucid disclaims any intention or obligation to
publicly update or revise any forward-looking statement to reflect
any change in its expectations or in events, conditions, or
circumstances on which those expectations may be based, or that may
affect the likelihood that actual results will differ from those
contained in the forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-holds-inaugural-checkyourfoodtube-precancer-testing-event-for-former-nfl-players-302263758.html
SOURCE Lucid Diagnostics
